← Back to Research Library

Bioregulator Peptides: What the Research on Pinealon Shows

Bioregulators are a family of short synthetic peptides. Much of the published work on them comes from Vladimir Khavinson and colleagues at the Saint Petersburg Institute of Bioregulation and Gerontology. Pinealon is one of them, a tripeptide of glutamic acid, aspartic acid and arginine. We found 22 records for Pinealon on PubMed (searched 16 October 2026), and of the papers cited here most list Khavinson or colleagues from his institute among the authors. This page sorts what has been published, in what kind of model, and says plainly where independent confirmation is missing.

This is a summary of published research, not a description of what any of these peptides does in a person.

On this page: What bioregulators are | Pinealon quick facts | What the research found | How it works | The rest of the family | Limits | Common questions

What bioregulators are

The name is the program’s own. It covers short peptides, two to four amino acids long. The group reports that the short sequences can enter cells and bind DNA and histone proteins, and that this is how they influence gene expression. That is the program’s working theory, set out in its own systematic review (Khavinson et al., 2021). It is not a settled mechanism.

Epithalon, the best known member, has its own page here: Epithalon research summary. Fourteen bioregulators are listed in the table near the end of this page. Only Pinealon has a section of its own so far, because its literature is the deepest.

Pinealon quick facts

• Names: Pinealon, EDR peptide, Glu-Asp-Arg. Pinealon is the program’s name for the tripeptide.
• Form in the literature: a short synthetic peptide. The papers below do not describe a vial or a product.

• Evidence: cell culture, rats, a physical-chemistry study of its binding to DNA, program reviews, and one small Russian-language human report. We found no registered trial (ClinicalTrials.gov, searched 16 October 2026).

What the research found

Each row below is one paper, grouped by kind of model. The authors’ affiliation is noted where the record shows it, because most of the work on Pinealon was done by one group. Papers marked Russian-language have English abstracts on PubMed and we did not read the full text.

Cells in a dish

Oxidative stress and cell survival (Khavinson, Rejuvenation Research, 2011). A study of cultured cerebellar granule cells, neutrophils and PC12 cells (a rat-derived cell line) under induced oxidative stress. The authors reported that Pinealon, at different concentrations, limited the build-up of reactive oxygen species and reduced cell death, delayed activation of the signaling protein ERK 1/2, and changed the cell cycle. They read the cell-cycle result as a sign that the peptide may interact with the cell’s genome, which is their interpretation. Cell work, from the program’s own institute. PMID 21978084.

Entry into the cell nucleus (Fedoreyeva, Biochemistry (Moscow), 2011). Fluorescence-labeled Epithalon, Pinealon and a third short peptide were seen inside HeLa cells, including the nucleus. In a separate test-tube experiment the peptides changed the fluorescence of labeled DNA fragments differently depending on their sequence, which the authors read as sequence-specific binding. Cell and test-tube work. Khavinson is a co-author. PMID 22117547.

Serotonin gene expression in brain-cortex cultures (Khavinson, Bulletin of Experimental Biology and Medicine, 2014). In cultures of brain cortex cells from aging animals, Pinealon and the peptide Lys-Glu-Asp raised expression of a serotonin-making enzyme. A computer docking analysis found a DNA sequence in the gene for that enzyme that the authors report is complementary to both peptides. Cell and computer work. The abstract does not give the species. PMID 24909721.

Neurons made from aged donors’ skin cells (Kraskovskaya, International Journal of Molecular Sciences, 2024). The newest cell study found. The authors turned dermal fibroblasts from elderly donors into cortical neurons in a dish and tested three short peptides, including Pinealon. All three increased branching of the neurons’ dendrites, and Pinealon reduced oxidative DNA damage. The two tripeptides had no effect on mitochondrial or lysosomal activity or on the aging marker p16. Cell work, with a co-author who also writes with the Khavinson group. PMID 39518916.

Rats

Offspring of rats on a high-methionine diet (Arutjunyan, International Journal of Clinical and Experimental Medicine, 2012). Pregnant rats on a methionine-loaded diet, a model of raised homocysteine, were given Pinealon. The authors reported that their offspring did better in a spatial learning test and that cerebellar neurons taken from the offspring had less reactive oxygen species build-up and fewer necrotic cells. The abstract gives no group sizes. Live animal model, not people. Khavinson is an author. PMID 22567179.

Low-oxygen stress in a hypobaric model (Kozina, Advances in Gerontology, 2008, Russian-language). Several short peptides were tested in a hypobaric hypoxia model, and the authors reported that Pinealon had the most pronounced effect of those tested. They propose that it works mainly by stimulating the cell’s own antioxidant enzymes rather than by blocking reactive oxygen species directly. The abstract does not name the species. PMID 18546825.

Aged rats under stress, compared with Cortexin (Mendzheritsky, Advances in Gerontology, 2015, Russian-language). A group in Rostov-on-Don tested Pinealon and Cortexin, a different peptide preparation, in 18-month-old rats under two stresses, acute low-oxygen pressure and mild cold. The authors reported that Cortexin had a stronger effect than Pinealon on free-radical processes and on caspase-3 activity in the brain, and that both were followed by higher levels of an adrenergic transmitter in rat brain under low oxygen and of serotonin in the cortex under cold. Three of the four authors on the PubMed record are at a university in Rostov-on-Don. The fourth is at the Saint Petersburg Institute of Bioregulation and Gerontology. It is the closest to an outside result we found, and in it Pinealon is the weaker of the two. PMID 28509493.

Physical chemistry

Binding to DNA (Silanteva, Journal of Physical Chemistry B, 2019). A physics group at Saint Petersburg State University used spectroscopy, NMR, viscosity and molecular dynamics to study how Glu-Asp-Arg interacts with DNA. They reported that the peptide can partly enter the major groove of DNA and affect atoms on guanine, and that magnesium ions help the interaction. No cells or animals. The authors on the PubMed record are not from the Khavinson institute. PMID 30762356.

People

A small report on Pinealon and a second peptide (Meshchaninov, Advances in Gerontology, 2015, Russian-language). Thirty-two adults aged 41 to 83 were given Pinealon or Vesugen, and the authors measured a set of cellular and metabolic markers. They reported changes on those markers, a pro-oxidant signal on one test, and lower counts of one blood stem-cell marker, which they read as reduced blood-cell formation. The abstract describes no placebo or comparison group. It is the only human report on Pinealon we found, it is small, and its authors’ own results are mixed. PMID 26390612.

The program’s own reviews

Mechanism review (Khavinson, Molecules, 2020). A review by the program’s group on how the EDR peptide might act on gene expression and protein synthesis. It collects the group’s earlier cell, animal and human reports and proposes pathways. It is an interpretation of earlier data, not a new experiment, and this page does not rely on its conclusions. PMID 33396470.

Systematic review of peptide gene regulation (Khavinson, Molecules, 2021). Another review from the same institute, covering short peptides in general. It is the source for the bioregulator mechanism described above, and it was written by the group whose work it reviews. PMID 34834147.

How it works, as far as anyone knows

The program proposes that very short peptides enter cells, reach the nucleus and bind DNA, changing which genes are read. The cell and test-tube papers above fit that picture, and the physics group at Saint Petersburg State University reports that EDR can sit in the DNA groove in a model system (Silanteva et al., 2019).

A second thread in the cell papers is the cell’s response to oxidative stress, where the program reports lower reactive oxygen species and changes in the ERK 1/2 pathway (Khavinson et al., 2011).

The two ideas do not yet join up. Binding to DNA in a test tube does not show what happens to gene expression in a living animal, and we found no paper that follows one chain from the peptide to a gene to a measured outcome in an animal. The mechanism is a proposal.

The rest of the family

Fourteen bioregulators are listed in the program’s literature. Only the sequence and length are stated here. A row in this table is not a research summary, and we have not summarized the studies on these peptides yet.

What the research does not establish

• Most of the Pinealon work we found was done by one research group. Of the papers cited here, most list Khavinson or colleagues from his institute among the authors. Findings from a single group are not the same as findings that independent labs have reproduced.
• Only one paper on this page, the physical-chemistry study, has no program author on its PubMed record. The Rostov rat study, in which Pinealon had the weaker effect, was run mostly outside the program but has one program-institute co-author. We found no independent replication of the cell results.
• Several of the papers are in Russian-language gerontology journals. We read English abstracts, not full text.
• The only human report is small, has no described comparison group, and its authors reported mixed results.
• We found no registered clinical trial of Pinealon (ClinicalTrials.gov, searched 16 October 2026).
• Animal and cell results do not transfer. What happened in cultured cells or in a rat does not show what would happen in a person.
• Nothing here is a safety conclusion. This is a research summary, and it does not show that any of these peptides is safe.

Common questions

What is Pinealon?

Pinealon is a synthetic tripeptide of glutamic acid, aspartic acid and arginine (Glu-Asp-Arg). The published work on it is mostly cell culture and rat studies, and most of it comes from one research program based in Saint Petersburg.

What does bioregulator mean?

Bioregulator is the research program’s own term for a short synthetic peptide of two to four amino acids. It is not a regulatory category or a standard chemical class.

Has Pinealon been studied in people?

We found one small report, in Russian, of 32 adults given Pinealon or Vesugen, and its abstract describes no comparison group (Meshchaninov et al., 2015). We found no registered clinical trial of Pinealon.

Is Pinealon the same as Epithalon?

No. Epithalon is a four-amino-acid peptide (Ala-Glu-Asp-Gly) and Pinealon is a three-amino-acid peptide (Glu-Asp-Arg). Both come from the same research program, and a 2011 cell study saw both inside HeLa cell nuclei (Fedoreyeva et al., 2011). Epithalon has its own research summary.

Why is the evidence described as thin?

The evidence is described as thin because most of it comes from one research group, in cell and rat models, with no independent replication that we found. The program’s reviews describe a consistent picture, and a consistent picture from one source is still one source.

Does Etched Research sell Pinealon?

Pinealon is not in the shop. The compounds Etched Research does carry are listed in the shop.

Why is there one page for fourteen peptides?

The published record for most bioregulators is small, so one page that states the limits once is more useful than fourteen thin ones. A peptide moves to its own page when the published work and the search interest justify it.

More in this research area: Epithalon | Research Library

Last reviewed 2026-10-16.

New reports, new research.

We send a note when a new lab report is posted or a compound comes back in stock, plus a short list of new research pages in any month we publish some. Never more than one email a week, and nothing else.

Please enable JavaScript in your browser to complete this form.

Address Email

Email Address *

Subscribe

For research use only. Not for human consumption.